Rise Therapeutics, a privately held, clinical-stage biotech in Rockville, Maryland, announced on September 22, 2026 that it completed dose escalation in the Phase 1 trial of R-5780 and is advancing the study into dose expansion after an independent Data Monitoring Committee reviewed the available safety data and supported the move.
President and CEO Gary Fanger said: “Completing dose escalation for R-5780 is a meaningful step in translating our novel immunotherapy approach into a potential option for people fighting cancer. Following its review of the available safety data, the independent Data Monitoring Committee supported advancing the study into dose expansion, where we will further evaluate R-5780’s safety and tolerability and explore its potential to enhance the effectiveness of immune checkpoint inhibitor therapy.”
An Oral Drug Aimed at Checkpoint-Refractory Tumors
R-5780 is an orally delivered, precision-directed synthetic biology medicine built on Rise’s proprietary oral biologics delivery platform, which taps into intestinal mechanisms that help control systemic immune biology. Rather than acting as a checkpoint inhibitor itself, R-5780 is designed to reset immunological repertoires in patients whose tumors have stopped responding to PD-1 checkpoint inhibitor therapy, with the goal of driving robust anti-tumor T cell activity and re-sensitizing those tumors to treatment. R-5780 is one of three Rise Therapeutics programs now in clinical testing on the same delivery platform, alongside ongoing studies in ulcerative colitis and in rheumatoid arthritis and Sjögren’s disease. The release doesn’t detail the specific biological pathway or dosing regimen involved.
Targeting a Large Gap in Checkpoint Inhibitor Response
The Phase 1 study (NCT06398418) is a multi-dose trial enrolling up to 33 participants total, designed to assess safety, drug exposure, and clinical activity; the newly opened dose expansion stage will further evaluate R-5780’s safety and tolerability alongside its potential to enhance checkpoint inhibitor effectiveness, though the release doesn’t disclose specific safety or efficacy data from the completed dose escalation. Rise frames the opportunity in market terms: the global immune checkpoint inhibitor market was valued at $49.8 billion in 2026 and is projected to reach $154.3 billion by 2030, even though roughly 80% of patients treated with current checkpoint inhibitors don’t benefit from them.
About Rise Therapeutics
Rise Therapeutics is a privately held, clinical-stage biotechnology company in Rockville, Maryland, leveraging synthetic biology and immunological drug development expertise to create novel oral immune therapies, with an emphasis on product development and internal clinical GMP manufacturing.
